IQVIA (IQV) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 May, 2026Executive summary
Q1 2026 revenue reached $4.151 billion, up 8.4% year-over-year, with strong organic growth in both Commercial and R&D Solutions segments.
Adjusted EBITDA was $932 million, up 5.5% year-over-year; Adjusted Diluted EPS rose to $2.90, up 7.4%, exceeding the high end of expectations.
Net income attributable to shareholders was $274 million, up from $249 million in Q1 2025.
Free Cash Flow was $491 million, up 15% year-over-year, representing 100% of Adjusted Net Income.
$552 million of common stock was repurchased during the quarter; $1.2 billion repurchase authorization remains.
Financial highlights
Operating Cash Flow was $618 million, up 9% year-over-year; cash and cash equivalents stood at $1.947 billion.
Net debt was $13.886 billion; gross debt $15.833 billion as of March 31, 2026.
Gross Margin for Q1 2026 was approximately 32.6%; Adjusted EBITDA margin was about 22.5%.
Adjusted Net Income was $492 million for the quarter.
Capital expenditures for Q1 2026 totaled $127 million.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at $17.15–$17.35 billion, with 150 bps from acquisitions and 100 bps FX tailwind.
Full-year Adjusted EBITDA guidance: $3.975–$4.025 billion; Adjusted Diluted EPS guidance raised to $12.65–$12.95.
Q2 2026 revenue guidance: $4.28–$4.34 billion; Adjusted EBITDA $955–$975 million; Adjusted Diluted EPS $2.98–$3.08.
Guidance assumes stable FX rates as of May 4, 2026.
Management expects available cash, operating cash flows, and credit facilities to fund requirements for at least the next 12 months.
Latest events from IQVIA
- AI-driven growth, robust data assets, and stable margins support a positive outlook.IQV
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day8 Apr 2026 - AI adoption, biotech growth, and new acquisitions drive optimism and margin expansion.IQV
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - AI-driven efficiencies and the Cedar Gate acquisition strengthen patient analytics and growth.IQV
Leerink Global Healthcare Conference 20269 Mar 2026 - 2025 results show robust growth, innovation, and governance, with all management proposals recommended.IQV
Proxy Filing27 Feb 2026 - Board recommends approval of all proposals except separating Chairman and CEO roles.IQV
Proxy Filing27 Feb 2026 - Strong 2025 results and 2026 outlook driven by AI, segment realignment, and robust demand.IQV
Q4 20255 Feb 2026 - Q2 revenue and profit margins rose, with record backlog and reaffirmed full-year guidance.IQV
Q2 20243 Feb 2026 - Strong R&DS and data-driven AI offset TAS volatility, supporting robust margins and growth outlook.IQV
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue up 4.3%, adjusted EPS up 14.1%, with strong TAS growth and $31.1B backlog.IQV
Q3 202417 Jan 2026